Grastofil (Filgrastim)

Grastofil is a prescription medication that contains the biologic agent filgrastim, a recombinant granulocyte‑colony stimulating factor. It is supplied in a sterile solution for intravenous or subcutaneous administration, though the exact strength and dosage form are not publicly disclosed. Filgrastim belongs to the hematopoietic growth‑factor class and works by stimulating the production and activation of neutrophil precursors. Grastofil is marketed in the European Union region.

Grastofil is indicated for several clinical situations in which neutrophil counts are compromised.

- Prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy. - Treatment of neutropenia associated with autologous or allogeneic bone‑marrow transplantation. - Management of severe chronic neutropenia (SCN) in patients with congenital or idiopathic forms. - Supportive therapy to reduce infection risk during radiation therapy that suppresses bone marrow. - Use in patients with acute leukemias undergoing intensive chemotherapy protocols.

The safety profile of Grastofil reflects filgrastim’s activity on bone‑marrow and immune cells, and reported adverse events are mainly linked to neutrophil stimulation.

Common: - Bone pain, especially in the lower back or hips, occurring after administration. - Musculoskeletal discomfort such as arthralgia or myalgia, usually transient. - Injection site reactions like erythema, swelling, or pruritus. - Fever or mild flu‑like symptoms, often self‑limited. - Nausea or mild gastrointestinal upset, such as cramping. - Headache or dizziness, usually mild and brief.

Serious: - Splenic rupture or enlargement, which can present with left‑upper‑quadrant pain. - Acute respiratory distress syndrome (ARDS), a rare but severe lung complication. - Severe allergic reactions such as anaphylaxis, requiring immediate medical attention. - Capillary leak syndrome, characterized by hypotension and edema. - Leukocytosis with very high white‑blood‑cell counts, potentially leading to vascular occlusion. - Severe thrombocytopenia or bleeding disorders, which may increase hemorrhage risk.

Precautions for Grastofil focus on patient selection, monitoring, and conditions that may exacerbate adverse reactions.

- Assess baseline neutrophil count and bone‑marrow function before initiating therapy. - Monitor complete blood count regularly to detect excessive leukocytosis or thrombocytopenia. - Use caution in patients with a history of splenic enlargement or trauma. - Avoid in individuals with known hypersensitivity to filgrastim or any component of the formulation. - Consider dose adjustment or discontinuation if severe bone pain or systemic reactions develop. - Evaluate renal and hepatic function, although dose changes are not routinely required.

Grastofil may interact with other agents that affect blood cell production, immune response, or clearance pathways.

Avoid: - Concomitant use of other granulocyte‑colony stimulating factors, which can increase risk of severe leukocytosis. - High‑dose chemotherapy agents that profoundly suppress bone marrow, as they may diminish the intended benefit. - Concurrent use of drugs that cause severe allergic reactions, such as monoclonal antibodies with known anaphylaxis risk, may compound hypersensitivity.

Use with caution: - Corticosteroids, because they may blunt the neutrophil response to filgrastim. - Antimicrobial agents that cause bone‑marrow suppression, such as chloramphenicol. - Immunosuppressive biologics (e.g., anti‑TNF agents) that could alter the clinical effect. - Renal replacement therapies (e.g., dialysis) may alter filgrastim clearance, requiring monitoring of blood counts.